SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 21, 2002; DOI 10.1182/blood-2002-02-0643. This Article Full Text (PDF) All Versions of this Article: 2002-02-0643v1 100/8/2874    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Guerra, N. Articles by Caignard, A. Search for Related Content PubMed PubMed Citation Articles by Guerra, N. Articles by Caignard, A. Social Bookmarking                   What's this? Submitted March 11, 2002 Accepted May 6, 2002 Engagement of the inhibitory receptor CD158a interrupts TCR signaling preventing dynamic membrane reorganization in CTL / tumor cell interaction Nadia Guerra, Frederique Michel, Asma Gati, Catherine Gaudin, Zohar Mishal, Bernard Escudier, Oreste Acuto, Salem Chouaib, and Anne Caignard* INSERM U487, Villejuif, France Unite d'Immunologie Moleculaire, Institut Pasteur, Paris, France Hopital Paul Brousse, Institut Andre Lwoff - CNRF, Villejuif, France Unite des Therapies innovantes, Institut Gustave Roussy, Villejuif, France * Corresponding author; email: caignard{at}igr.fr. Renal cell carcinoma (RCC) infiltrating lymphocytes (TIL) express Killer cell Ig-like receptors (KIR) that inhibit the antitumor CD8+T cell lysis. In the present study, to better examine the functional consequences of KIR engagement on CTL/Tumor interaction, we have investigated the influence of KIR CD158a on early steps of T cell activation. We show that coengagement of TCR and CD158a by tumor cells inhibited tyrosine phosphorylation of early signaling proteins ZAP-70 and LAT, lipid rafts coalescence and TCR/CD3 accumulation at the CTL/tumor cell interface. In addition, the guanine exchange factor Vav was not phosphorylated and no actin cytoskeleton rearrangement was observed. Our data indicate a role of KIR CD158a in the dynamic events induced by TCR triggering, preventing CTL membrane reorganization, and subsequent completion of CTL activation program. Accordingly, the expression of CD158 by TIL may favor tumor cell escape to the immune response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. T. van der Veken, M. Diez Campelo, M. A. W. G. van der Hoorn, R. S. Hagedoorn, H. M. E. van Egmond, J. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. H. M. Heemskerk Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8+ T Cells J. Immunol., January 1, 2009; 182(1): 92 - 101. [Abstract] [Full Text] [PDF] G. Alter, S. Rihn, H. Streeck, N. Teigen, A. Piechocka-Trocha, K. Moss, K. Cohen, A. Meier, F. Pereyra, B. Walker, et al. Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection J. Virol., October 1, 2008; 82(19): 9668 - 9677. [Abstract] [Full Text] [PDF] E. Fourmentraux-Neves, A. Jalil, S. Da Rocha, C. Pichon, S. Chouaib, G. Bismuth, and A. Caignard Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells Blood, September 15, 2008; 112(6): 2381 - 2389. [Abstract] [Full Text] [PDF] E. G. Iliopoulou, M. V. Karamouzis, I. Missitzis, A. Ardavanis, N. N. Sotiriadou, C. N. Baxevanis, G. Rigatos, M. Papamichail, and S. A. Perez Increased Frequency of CD4+ Cells Expressing CD161 in Cancer Patients Clin. Cancer Res., December 1, 2006; 12(23): 6901 - 6909. [Abstract] [Full Text] [PDF] J. A. Campillo, J. A. Martinez-Escribano, M. R. Moya-Quiles, L. A. Marin, M. Muro, N. Guerra, A. Parrado, M. Campos, J. F. Frias, A. Minguela, et al. Natural Killer Receptors on CD8 T Cells and Natural Killer Cells from Different HLA-C Phenotypes in Melanoma Patients. Clin. Cancer Res., August 15, 2006; 12(16): 4822 - 4831. [Abstract] [Full Text] [PDF] G. Henel, K. Singh, D. Cui, S. Pryshchep, W.-W. Lee, C. M. Weyand, and J. J. Goronzy Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors Blood, June 1, 2006; 107(11): 4449 - 4457. [Abstract] [Full Text] [PDF] A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF] G. Dorothee, I. Vergnon, F. El Hage, B. L. M. Chansac, V. Ferrand, Y. Lecluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity J. Immunol., June 1, 2005; 174(11): 6888 - 6897. [Abstract] [Full Text] [PDF] A. Gati, N. Guerra, C. Gaudin, S. Da Rocha, B. Escudier, Y. Lecluse, A. Bettaieb, S. Chouaib, and A. Caignard CD158 Receptor Controls Cytotoxic T-Lymphocyte Susceptibility to Tumor-Mediated Activation-Induced Cell Death by Interfering with Fas Signaling Cancer Res., November 1, 2003; 63(21): 7475 - 7482. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020